Mohamad H. Yamani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mohamad H. Yamani has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
Randall C. Starling
17 shared publicationsJames B. Young
14 shared publicationsNorman B. Ratliff
12 shared publicationsDaniel J. Cook
11 shared publicationsRobert Hobbs
Departments of Cardiovascular Medicine
11 shared publicationsGustavo Rincon
8 shared publications
Latest Publications
- 24 October 2007
- Published by Wiley in Clinical Transplantation
- Vol. 22 (1) , 76-81
Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study
Abstract: Background: Chronic use of corticosteroids (CS) following transplantation is associated with significant long‐term morbidities. Minimizing exposure to CS to improve long‐term outcomes, without compromising allograft function, remains an important goal in transplantation.Objectives: This single‐center, prospective, randomized, open‐label study was designed to evaluate the efficacy of Thymoglobulin® as part of a CS‐sparing regimen in cardiac transplantation.Methods: Thirty‐two low‐risk cardiac transplant patients were randomized in a 1:1 ratio to receive either a Thymoglobulin‐based CS‐avoidance regimen (CS‐avoidance group; n = 16) or a long‐term CS‐based regimen with no antibody induction (control group; n = 16). Pulse CS therapy was used for the treatment of acute cellular rejection in both groups.Results: Baseline characteristics were similar between groups. At one yr, there was no significant difference in the mean incidence of acute cellular rejection (≥3A) episodes between the CS‐avoidance and control groups, 0.81 ± 1.05 and 1.07 ± 1.03, respectively. Importantly, the CS‐avoidance patients had significant improvement in muscle strength and less bone loss compared with the control patients during the first six months post‐transplant.Conclusions: CS‐avoidance regimen with Thymoglobulin induction appeared to be safe and effective in cardiac transplantation. Further studies are required to demonstrate the long‐term safety and benefits of such a regimen.
- 24 October 2007
- Published by Wiley in Clinical Transplantation
- Vol. 22 (1) , 76-81
Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study
Abstract: Background: Chronic use of corticosteroids (CS) following transplantation is associated with significant long‐term morbidities. Minimizing exposure to CS to improve long‐term outcomes, without compromising allograft function, remains an important goal in transplantation.Objectives: This single‐center, prospective, randomized, open‐label study was designed to evaluate the efficacy of Thymoglobulin® as part of a CS‐sparing regimen in cardiac transplantation.Methods: Thirty‐two low‐risk cardiac transplant patients were randomized in a 1:1 ratio to receive either a Thymoglobulin‐based CS‐avoidance regimen (CS‐avoidance group; n = 16) or a long‐term CS‐based regimen with no antibody induction (control group; n = 16). Pulse CS therapy was used for the treatment of acute cellular rejection in both groups.Results: Baseline characteristics were similar between groups. At one yr, there was no significant difference in the mean incidence of acute cellular rejection (≥3A) episodes between the CS‐avoidance and control groups, 0.81 ± 1.05 and 1.07 ± 1.03, respectively. Importantly, the CS‐avoidance patients had significant improvement in muscle strength and less bone loss compared with the control patients during the first six months post‐transplant.Conclusions: CS‐avoidance regimen with Thymoglobulin induction appeared to be safe and effective in cardiac transplantation. Further studies are required to demonstrate the long‐term safety and benefits of such a regimen.
- 31 August 2007
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 13 (6) , S126
The Prevalence of Atrial Fibrillation in Patients with Congestive Heart Failure and Hypogammaglobulinemia
- 31 August 2007
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 13 (6) , S126
The Prevalence of Atrial Fibrillation in Patients with Congestive Heart Failure and Hypogammaglobulinemia
- 30 June 2007
- Published by Wiley in Clinical Transplantation
- Vol. 21 (4) , 523-525
Post‐transplant ischemic injury is associated with up‐regulated AlloMap gene expression
The AlloMap gene expression test is used for the non-invasive detection of rejection. However, the impact of early post-transplant ischemic injury on subsequent AlloMap gene expression analysis has not been evaluated before. Sixty seven heart transplant recipients, mean age 53 years, were evaluated at a mean 34 months post-transplant. AlloMap score was determined on the same day of heart biopsies. Nineteen patients had evidence of early post-transplant ischemic injury (Injury group). These were compared with the remaining 48 patients, Control group. Using multiple regression model with a backward selection method, post-transplant ischemic injury was found to be associated with significant increased AlloMap score compared with controls (31.5 +/- 4.6 vs. 26 +/- 6.2, p < 0.001). The Injury group had increased transplant vasculopathy (KM 5-year freedom from vasculopathy: 34% vs. 52%, p = 0.015), than Controls. Post-transplant ischemic injury is associated with up-regulated AlloMap gene expression, and hence, may provide another explanation for a high score in the absence of rejection.
- 30 June 2007
- Published by Wiley in Clinical Transplantation
- Vol. 21 (4) , 523-525
Post‐transplant ischemic injury is associated with up‐regulated AlloMap gene expression
The AlloMap gene expression test is used for the non-invasive detection of rejection. However, the impact of early post-transplant ischemic injury on subsequent AlloMap gene expression analysis has not been evaluated before. Sixty seven heart transplant recipients, mean age 53 years, were evaluated at a mean 34 months post-transplant. AlloMap score was determined on the same day of heart biopsies. Nineteen patients had evidence of early post-transplant ischemic injury (Injury group). These were compared with the remaining 48 patients, Control group. Using multiple regression model with a backward selection method, post-transplant ischemic injury was found to be associated with significant increased AlloMap score compared with controls (31.5 +/- 4.6 vs. 26 +/- 6.2, p < 0.001). The Injury group had increased transplant vasculopathy (KM 5-year freedom from vasculopathy: 34% vs. 52%, p = 0.015), than Controls. Post-transplant ischemic injury is associated with up-regulated AlloMap gene expression, and hence, may provide another explanation for a high score in the absence of rejection.
- 1 April 2007
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 26 (4) , 403-406
Transplant Vasculopathy Is Associated With Increased AlloMap Gene Expression Score
- 1 April 2007
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 26 (4) , 403-406
Transplant Vasculopathy Is Associated With Increased AlloMap Gene Expression Score
- 1 February 2007
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 74 (Suppl_1) , S110
Heart transplantation: a magnified model of heart-brain interactions.
The human heart transplant model unmasks the heart-brain link as an active process that is clinically demonstrated and confirmed at the tissue level. Further studies are needed to elucidate the relative contribution of each of these isolated observations to the pathogenesis of coronary allograft vasculopathy, which remains enigmatic. Recent studies have suggested that mTOR inhibitors may have the ability to attenuate this lethal process that limits the long-term survival of cardiac transplant recipients. The observations we have discussed here suggest that other targeted therapies, including glycoprotein IIb/IIIa inhibitors, tissue metalloproteinase inhibitors, and angiotensin receptor blockers, may facilitate the attenuation of cardiac transplant vasculopathy, but clinical trials are difficult to conduct in this relatively small population of patients. These observations may shed insight, however, into the pathophysiology of hypertension and its impact on the vascular system, as cardiac transplantation provides a setting in which heart-brain interactions are magnified and the pathophysiology occurs over years rather than decades.
- 1 February 2007
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 74 (Suppl_1) , S110
Heart transplantation: a magnified model of heart-brain interactions.
The human heart transplant model unmasks the heart-brain link as an active process that is clinically demonstrated and confirmed at the tissue level. Further studies are needed to elucidate the relative contribution of each of these isolated observations to the pathogenesis of coronary allograft vasculopathy, which remains enigmatic. Recent studies have suggested that mTOR inhibitors may have the ability to attenuate this lethal process that limits the long-term survival of cardiac transplant recipients. The observations we have discussed here suggest that other targeted therapies, including glycoprotein IIb/IIIa inhibitors, tissue metalloproteinase inhibitors, and angiotensin receptor blockers, may facilitate the attenuation of cardiac transplant vasculopathy, but clinical trials are difficult to conduct in this relatively small population of patients. These observations may shed insight, however, into the pathophysiology of hypertension and its impact on the vascular system, as cardiac transplantation provides a setting in which heart-brain interactions are magnified and the pathophysiology occurs over years rather than decades.
- 1 November 2006
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 25 (11) , 1283-1289
Increased Expression of Angiotensin II Type 1 Receptor (AGTR1) in Heart Transplant Recipients With Recurrent Rejection
- 1 November 2006
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 25 (11) , 1283-1289
Increased Expression of Angiotensin II Type 1 Receptor (AGTR1) in Heart Transplant Recipients With Recurrent Rejection
- 1 July 2006
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 25 (7) , 820-824
The Impact of Hypogammaglobulinemia on Infection Outcome in Patients Undergoing Ventricular Assist Device Implantation
- 1 July 2006
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 25 (7) , 820-824
The Impact of Hypogammaglobulinemia on Infection Outcome in Patients Undergoing Ventricular Assist Device Implantation
- 1 November 2005
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 24 (11) , 1766-1769
The Impact of CytoGam on Cardiac Transplant Recipients With Moderate Hypogammaglobulinemia: A Randomized Single-Center Study
- 1 November 2005
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 24 (11) , 1766-1769
The Impact of CytoGam on Cardiac Transplant Recipients With Moderate Hypogammaglobulinemia: A Randomized Single-Center Study
- 1 November 2005
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 24 (11) , 1741-1744
The Impact of Donor Gender on Cardiac Peri-transplantation Ischemia Injury
- 1 November 2005
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 24 (11) , 1741-1744
The Impact of Donor Gender on Cardiac Peri-transplantation Ischemia Injury